Skip to main content

Table 3 Number of oocytes and total gonadotrophin dose for hMG versus r-hFSH

From: Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis

Studied endpoint for hMG versus r-hFSH MD 95% CI p value SDM 95% CI P value
Number of oocytes       
   - Main analysis -1.54 -2.53, -0.56 < 0.0001 -0.23 -0.36, -0.10 < 0.0001
   - Sub-group 1 -1.68 -2.69, -0.68 < 0.0001 -0.25 -0.38, -0.12 < 0.0001
   - Sub-group 2 -1.57 -2.65, -0.49 < 0.001 -0.24 -0.38, -0.11 < 0.0001
   - Main analysis (fixed model) -1.74 -2.12, -1.35 < 0.0001 -0.26 -0.32, -0.19 < 0.0001
Number of oocytes adjusted for baseline -2.10 -2.83, -1.36 < 0.001 -0.35 -0.47, -0.22 < 0.0001
Dosage (IU) 235.46 16.62, 454.30 0.03 0.33 0.08, 0.58 0.01
  1. hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; MD = mean difference; SDM = standardized mean difference